Ozempic® (semaglutide) is the original once-weekly GLP-1 injection, FDA-approved for type 2 diabetes — improving blood sugar and protecting the heart and kidneys. Prescribed online by licensed physicians and shipped to your door.
Once-weekly injectable · FDA-approved for type 2 diabetes
Ozempic® is a once-weekly semaglutide injection from Novo Nordisk, FDA-approved to improve blood-sugar control in adults with type 2 diabetes. It is a GLP-1 receptor agonist — it mimics a natural gut hormone that prompts insulin release when blood sugar is high, slows digestion, and reduces appetite.
Beyond blood sugar, Ozempic® is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and heart disease, and to protect kidney function in those with type 2 diabetes and chronic kidney disease. It contains the same active ingredient as Wegovy® and Rybelsus®, though each brand has its own approved uses and doses.
Ozempic® mimics GLP-1, a hormone your gut releases after eating. That single signal does several things at once to help manage type 2 diabetes.
It prompts the pancreas to release insulin when blood sugar is high and dials back glucagon — tighter control with lower risk of lows.
By slowing how quickly the stomach empties, it blunts the blood-sugar spikes that follow meals and helps you feel full longer.
Like other GLP-1s, it acts on hunger signals, which is why many people eat less while taking it.
In adults with type 2 diabetes, Ozempic® is also approved to lower the risk of major cardiovascular events and to slow kidney decline.
Every Ozempic® indication is tied to type 2 diabetes in adults. Here's exactly what the FDA label covers.
As an add-on to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
To reduce the risk of major cardiovascular events — cardiovascular death, heart attack, or stroke — in adults with type 2 diabetes and established heart disease.
To reduce the risk of sustained kidney-function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Ozempic® is not FDA-approved for weight loss — that's its sibling Wegovy® (the same medicine, semaglutide, at a higher dose). Tell us your goals and our physicians will recommend the right, appropriate option for you.
Ozempic® starts low and increases over time so your body can adjust and side effects stay manageable. It's a once-weekly injection at every step.
The 0.25 mg starting dose helps your body adjust and isn't a maintenance dose. Your physician steps you up about every 4 weeks based on your blood-sugar goals and how you tolerate the medication — many people stay at 0.5 mg or 1 mg. Always follow your prescriber's instructions.
Ozempic® was studied in the SUSTAIN program in adults with type 2 diabetes. These are the headline, approved outcomes — individual results vary.
In clinical trials, Ozempic® lowered A1C (a measure of long-term blood sugar) by up to about 1.8% at the higher dose, helping many adults with type 2 diabetes reach their blood-sugar targets alongside diet and exercise.
Beyond blood sugar, Ozempic® is FDA-approved to reduce the risk of major cardiovascular events in adults with T2D and heart disease, and to slow kidney-function decline in adults with T2D and chronic kidney disease.
* Based on the SUSTAIN clinical program in adults with type 2 diabetes. Ozempic® is not FDA-approved for weight loss. Individual results vary based on dose, adherence, and health history.
Same ingredient, different brands and approvals. Here's how Ozempic® compares with the related medications people ask about.
| Feature | Ozempic® | Wegovy® | Rybelsus® | Mounjaro® |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide | Tirzepatide |
| Form | Injection | Injection | Oral tablet | Injection |
| Primary FDA use | Type 2 diabetes | Weight management | Type 2 diabetes | Type 2 diabetes |
| Administration | Weekly injection | Weekly injection | Daily pill | Weekly injection |
| Approved for weight loss | No (off-label) | Yes | No | No (Zepbound® is) |
| Brand maker | Novo Nordisk | Novo Nordisk | Novo Nordisk | Eli Lilly |
Ozempic®, Rybelsus®, and Mounjaro® are not FDA-approved for weight loss. Your physician will recommend the most appropriate option for your diagnosis and goals.
Coverage for Ozempic® is often strongest when it's prescribed for type 2 diabetes. Our care team helps you find the most affordable path.
A prescription is only part of the picture. Your program wraps the medication in ongoing clinical care and support to help you succeed.
If it's appropriate for you, your physician prescribes Ozempic® at the right dose.
Secure telemedicine evaluations and follow-ups with licensed providers — no waiting rooms.
Guidance on titration and managing common side effects, with a team you can message.
Coordinators check coverage, apply savings programs, and lay out cash-pay options.
Track blood-sugar goals, doses, and milestones so you and your provider can see what's working.
Medication ships from a licensed pharmacy directly to your door, refilled on schedule.
Our telemedicine process is fast, private, and designed to take you from consultation to prescription as smoothly as possible.
Tell us about your medical history and health goals to see if you medically qualify — no cost, no obligation.
A licensed physician reviews your assessment, diagnosis, and goals via a secure telemedicine visit.
If Ozempic® is appropriate, your physician issues your prescription and your starting dose.
Your medication ships from a licensed pharmacy to your door, with ongoing monthly clinical support included.
Eligibility is always determined by a licensed physician during your clinical evaluation. These are the general guidelines.
Take the free quiz and our care team will help you understand your options — including whether Ozempic® or another medication is the right fit. No commitment required.
Medication works best as part of a routine. These habits support steady blood sugar, ease side effects, and build lasting health.
Consistent, balanced meals support smoother blood-sugar control and make GI side effects easier to manage.
Regular movement improves insulin sensitivity and complements the medication's blood-sugar benefits.
Plenty of water and fiber-rich foods help manage common digestive side effects like constipation.
Pick a consistent weekly injection day so the medication stays at steady levels and you don't miss doses.
Monitoring blood sugar (and weight, if relevant) helps you and your provider fine-tune your plan.
Ongoing check-ins keep you on track and make managing a chronic condition feel less isolating.
Most side effects are gastrointestinal and typically mild, most common at the start or after a dose increase, and improve as your body adjusts.
Most common at the start or after dose increases. Usually mild and eases within a few weeks. Smaller meals help.
Changes in digestion are common. Staying hydrated and keeping up fiber intake helps manage symptoms.
Bloating, fullness, or mild abdominal pain — especially after eating. Typically resolves as your body adjusts.
A common GLP-1 effect. Make sure you're still meeting your nutritional needs.
Low blood sugar risk rises if combined with insulin or sulfonylureas. Your physician may adjust those doses.
Mild redness or swelling at the site. Rotating injection sites helps. Resolves quickly in most cases.
Report severe upper-abdominal pain, fever, or jaundice promptly, as gallbladder problems can occur.
Very rare but serious. Stop the medication and contact your physician immediately if you have severe, persistent abdominal pain.
Important: Ozempic® carries a boxed warning regarding the risk of thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. This is a general overview and not a complete list of side effects or warnings. Your physician will review your full health history and explain all relevant risks during your evaluation. Always follow your physician's dosing instructions and report unusual symptoms promptly. Read full Important Safety Information →
A few simple practices keep your medication effective and your injections comfortable. Always follow the instructions that come with your pen.
Store new pens in the refrigerator. Do not freeze — discard any pen that has frozen.
An in-use pen can be kept at room temperature or refrigerated for a limited time per the label. Check your product instructions.
Inject into the abdomen, thigh, or upper arm, rotating the site each week, and inject on the same day weekly.
Place used pens and needles in an FDA-cleared sharps container — never loose in household trash.
If it's within 5 days, take it when you remember; if more than 5 days, skip it. Don't double up — ask your provider.
Reach your care team about severe or persistent side effects, signs of an allergic reaction, or questions about your dose.
Fast Medical Weight Loss pairs FDA-approved medication with real clinical oversight and a process built around you.
Every prescription is evaluated and issued by a licensed provider — never an automated checkout.
Nationwide telemedicine access, with visits conducted by secure video or questionnaire.
Medication ships from licensed pharmacies straight to your door in plain packaging.
Your health information is protected at every step of your care.
Clear cash-pay rates plus insurance support — no surprise fees, cancel anytime.
A care team for dosing questions, side effects, and refills throughout your journey.
All-inclusive programs — licensed-physician visits and your medication included. No membership fees, cancel anytime. Multi-month plans save you more.
The 3-month and 6-month plans are billed once and are discounted versus the monthly rate. All medication requires a licensed-physician evaluation and prescription.
Clear answers to the most common questions about Ozempic®, semaglutide, and our telemedicine program.
No. Ozempic® is FDA-approved for type 2 diabetes (and to reduce heart and kidney risk in people with T2D). Many people lose weight on it, but that use is off-label. The FDA-approved weight-loss form of semaglutide is Wegovy®.
Both contain semaglutide. Ozempic® is approved for type 2 diabetes at doses up to 2 mg. Wegovy® is approved specifically for weight management and uses a higher 2.4 mg dose. Your physician will determine which is appropriate.
Ozempic® is semaglutide (a GLP-1). Mounjaro® is tirzepatide, which targets two hormone receptors (GLP-1 and GIP). Both are approved for type 2 diabetes; neither is FDA-approved for weight loss (Wegovy® and Zepbound® are, respectively).
It's often covered when prescribed for type 2 diabetes, and our coordinators will work with your plan and any savings programs. Coverage for off-label use is less likely; cash-pay options are available.
Many people see blood-sugar improvements within the first several weeks, with fuller effects as the dose is titrated up over a couple of months. Your physician will track your A1C and adjust accordingly.
Store new pens in the refrigerator. Once a pen is in use, it can be kept at room temperature or refrigerated for a limited time per the label. Never freeze it.
If you remember within 5 days, take it as soon as you can. If more than 5 days have passed, skip the missed dose and resume your regular weekly schedule. Don't take two doses close together.
Evaluations are conducted via secure video or an asynchronous questionnaire, depending on your state and preference. All visits are HIPAA-compliant and conducted by licensed physicians.
Take the free quiz and let a licensed physician determine whether Ozempic® — or another medication — is right for your diagnosis, goals, and budget.
Start My Free ConsultationOzempic®, Wegovy®, Rybelsus®, and NovoCare® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. This page has not been reviewed or endorsed by Novo Nordisk or Eli Lilly. Ozempic® (semaglutide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic® is not FDA-approved for weight loss; semaglutide is approved for chronic weight management under the brand name Wegovy®. *A1C reduction figures are from the SUSTAIN clinical program in adults with type 2 diabetes; individual results vary. ‡The $299/month program includes licensed-physician visits and a monthly medication supply, with no membership fees; cancel anytime. The 3-month and 6-month plans are billed once and are discounted versus the monthly rate. Pricing shown is illustrative and subject to change. Ozempic® carries a boxed warning regarding the risk of thyroid C-cell tumors. This page is for informational purposes only and does not constitute medical advice. All treatment requires a licensed physician evaluation, eligibility, and a prescription; not all patients will qualify. Prescriptions require an online consultation with a healthcare provider who will determine whether a prescription is appropriate. Medication is dispensed through licensed pharmacies. ©2026 Fast Medical Weight Loss. HIPAA Compliant. All Rights Reserved.
©2026 All Rights Reserved. fastmedicalweightloss.org
